California State Teachers Retirement System Trims Stock Position in OrthoPediatrics Corp. (NASDAQ:KIDS)

California State Teachers Retirement System cut its holdings in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) by 6.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,796 shares of the company’s stock after selling 952 shares during the quarter. California State Teachers Retirement System’s holdings in OrthoPediatrics were worth $343,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new position in shares of OrthoPediatrics in the 4th quarter worth about $79,000. AlphaCentric Advisors LLC purchased a new position in shares of OrthoPediatrics in the 4th quarter worth about $171,000. Wells Fargo & Company MN raised its holdings in shares of OrthoPediatrics by 31.1% in the 4th quarter. Wells Fargo & Company MN now owns 9,853 shares of the company’s stock worth $228,000 after purchasing an additional 2,338 shares during the period. HighTower Advisors LLC purchased a new position in shares of OrthoPediatrics in the 4th quarter worth about $268,000. Finally, Deutsche Bank AG raised its holdings in shares of OrthoPediatrics by 57.1% in the 4th quarter. Deutsche Bank AG now owns 14,393 shares of the company’s stock worth $334,000 after purchasing an additional 5,233 shares during the period. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at OrthoPediatrics

In other OrthoPediatrics news, General Counsel Daniel J. Gerritzen sold 5,310 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the completion of the sale, the general counsel now owns 110,767 shares in the company, valued at $2,753,667.62. This trade represents a 4.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gregory A. Odle sold 5,359 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $133,224.74. Following the sale, the insider now owns 148,788 shares of the company’s stock, valued at approximately $3,698,869.68. This trade represents a 3.48% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,732 shares of company stock worth $589,978 in the last 90 days. 32.70% of the stock is owned by corporate insiders.

OrthoPediatrics Stock Performance

Shares of NASDAQ:KIDS opened at $21.72 on Friday. The company has a market cap of $527.51 million, a P/E ratio of -17.66 and a beta of 1.08. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. OrthoPediatrics Corp. has a one year low of $19.52 and a one year high of $35.99. The business’s 50-day simple moving average is $21.53 and its 200 day simple moving average is $23.35.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Wednesday, May 7th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.13). The company had revenue of $52.41 million for the quarter, compared to analysts’ expectations of $51.68 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. On average, sell-side analysts forecast that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Needham & Company LLC restated a “buy” rating and issued a $42.00 price objective on shares of OrthoPediatrics in a report on Thursday, May 8th. Lake Street Capital assumed coverage on OrthoPediatrics in a report on Monday, April 7th. They issued a “buy” rating and a $37.00 price objective on the stock. Stifel Nicolaus cut their price objective on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th. Piper Sandler dropped their target price on OrthoPediatrics from $40.00 to $30.00 and set an “overweight” rating on the stock in a report on Thursday, May 8th. Finally, Wall Street Zen downgraded OrthoPediatrics from a “hold” rating to a “sell” rating in a report on Friday, June 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.83.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.